Vaginal Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VGN020 MIFTS: 50	Vaginal Disease Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Vaginal Disease

MalaCards integrated aliases for Vaginal Disease:

Name: Vaginal Disease ¹² ¹⁵

Vaginal Diseases ⁴² ⁴³ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:121

MeSH ⁴³ D014623

NCIt ⁴⁹ C26910

SNOMED-CT ⁶⁷ 25658005

UMLS ⁷¹ C0042251

Sources

Summaries for Vaginal Disease

MedlinePlus : ⁴² Vaginal problems are some of the most common reasons women go to the doctor. They may have symptoms such as Itching Burning Pain Abnormal bleeding Discharge One common problem is vaginitis, an inflammation of the vagina. Other problems that affect the vagina include sexually transmitted diseases, vaginal cancer, and vulvar cancer. Treatment of vaginal problems depends on the cause.

MalaCards based summary : Vaginal Disease, also known as vaginal diseases, is related to vaginal discharge and vaginitis, and has symptoms including pelvic pain and leukorrhea. An important gene associated with Vaginal Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Etonogestrel and Norethindrone have been mentioned in the context of this disorder. Affiliated tissues include vagina, bone and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : ¹² A female reproductive system disease that is located in the vagina.

Wikipedia : ⁷⁴ A vaginal disease is a pathological condition that affects part or all of the... more...

Sources

Related Diseases for Vaginal Disease

Diseases related to Vaginal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)

#	Related Disease	Score	Top Affiliating Genes
1	vaginal discharge	32.4	SLPI IL6 CXCL8 CD4
2	vaginitis	31.6	TNF TLR4 TLR2 SLPI IL6 IL1B
3	genital herpes	30.1	TLR2 IL10 CD8A CD4 CCR6
4	trichomoniasis	29.9	TNF SLPI IL6 CXCL8 CD4 CCR5
5	herpes simplex	29.9	TNF TLR9 TLR3 TLR2 CD8A
6	cervical cancer	29.3	TNF TLR9 TLR4 IL6 IL10 CXCL8
7	leukoplakia of vagina	11.0
8	mycobacterium chelonae	10.7	TLR2 CXCL8
9	external pathological resorption	10.7	TNF IL6
10	cork-handlers' disease	10.7	CD8A CD4
11	subcutaneous mycosis	10.7	TLR7 CLEC7A CCR6
12	cutaneous candidiasis	10.7	TLR3 CLEC7A CCR6
13	spongiotic dermatitis	10.7	CD8A CD4 CCR6
14	syphilitic meningitis	10.7	CD8A CD4
15	mycobacterium marinum	10.6	TLR2 CXCL8
16	scorpion envenomation	10.6	TNF IL6
17	dermatophytosis	10.6	CLEC7A CD4 CCR6
18	esophageal candidiasis	10.6	CD8A CD4 CCR6
19	mucormycosis	10.6	CLEC7A CD4 CCR6
20	cardiomyopathy, familial hypertrophic, 20	10.6	IL6 CXCL8 CD4
21	t-cell adult acute lymphocytic leukemia	10.6	CD8A CD4 CCR6
22	adult acute lymphocytic leukemia	10.6	CD8A CD4 CCR6
23	autoimmune glomerulonephritis	10.6	CD8A CD4 CCR6
24	ventilation pneumonitis	10.6	CD8A CD4
25	denture stomatitis	10.6	IL6 CXCL8 CLEC7A
26	plasma protein metabolism disease	10.6	IL6 CD4 CCR6
27	epididymis disease	10.6	TLR4 IL6 CD4
28	borst-jadassohn intraepidermal carcinoma	10.6	TLR7 LINC01191 CD8A
29	polyclonal hypergammaglobulinemia	10.6	IL6 CD8A CD4
30	pustulosis of palm and sole	10.6	TNF CXCL8 CCR6
31	chancroid	10.6	CD4 CCR6 CCR5
32	punctate inner choroidopathy	10.6	TNF IL10
33	idiopathic anterior uveitis	10.6	TNF IL6 CXCL8
34	streptococcal toxic-shock syndrome	10.6	TNF IL6 CXCL8
35	acute proliferative glomerulonephritis	10.6	TNF CD4 CCR6
36	mikulicz disease	10.6	IL10 CD4 CCR6
37	t cell deficiency	10.6	CD8A CD4 CCR6
38	necrotizing fasciitis	10.6	IL6 H2AC18 CXCL8
39	immunoglobulin alpha deficiency	10.6	CD8A CD4 CCR6
40	mycobacterium kansasii	10.6	TLR2 CXCL8
41	angelucci's syndrome	10.6	IL1B CXCL8
42	recurrent corneal erosion	10.6	IL6 IL1B CXCL8
43	fungal keratitis	10.6	TLR4 TLR2 CLEC7A
44	diffuse infiltrative lymphocytosis syndrome	10.6	CD8A CD4
45	lung abscess	10.6	TNF IL6 CD4
46	autoimmune lymphoproliferative syndrome, type iia	10.6	CD8A CD4
47	diabetes mellitus, insulin-dependent, 23	10.6	TNF CD8A CD4
48	brachydactyly, type c	10.6	CD8A CD4 CCR6
49	hemorrhagic cystitis	10.6	TLR4 CD8A CD4
50	peptic esophagitis	10.6	IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Vaginal Disease:

Sources

Symptoms & Phenotypes for Vaginal Disease

UMLS symptoms related to Vaginal Disease:

pelvic pain, leukorrhea

MGI Mouse Phenotypes related to Vaginal Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.22	CCR5 CCR6 CD4 CD8A CLEC7A IL10
2	homeostasis/metabolism	MP:0005376	10.16	CCR5 CCR6 CD4 CLEC7A GP5 IL10
3	immune system	MP:0005387	10.06	CCR5 CCR6 CD4 CD8A CLEC7A IL10
4	digestive/alimentary	MP:0005381	10.02	CCR5 CD4 CLEC7A IL10 IL6 TLR2
5	mortality/aging	MP:0010768	9.8	CCR5 CD4 CD8A CLEC7A IL10 IL1B
6	neoplasm	MP:0002006	9.23	CCR5 IL10 IL1B IL6 TLR2 TLR3

Sources

Drugs & Therapeutics for Vaginal Disease

Drugs for Vaginal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Etonogestrel

Approved, Investigational

Phase 4

54048-10-1

40976 6917715

Norethindrone

Approved

Phase 4

68-22-4

6230

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Tinidazole

Approved, Investigational

Phase 4

19387-91-8

5479

Clindamycin

Approved, Vet_approved

Phase 4

18323-44-9

29029

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Desogestrel

Approved

Phase 4

54024-22-5

40973

Ethinyl Estradiol

Approved

Phase 4

57-63-6

5991

Azithromycin

Approved

Phase 4

83905-01-5

55185 447043

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Desflurane

Approved

Phase 4

57041-67-5

42113

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Secnidazole

Approved

Phase 4

3366-95-8

Metronidazole

Approved

Phase 4

443-48-1

4173

Cysteine

Approved, Nutraceutical

Phase 4

52-90-4

5862

Norethindrone enanthate

Experimental

Phase 4

3836-23-5

Antiviral Agents

Phase 4

Norethindrone Acetate

Phase 4

Antioxidants

Phase 4

Free Radical Scavengers

Phase 4

N-monoacetylcystine

Phase 4

Respiratory System Agents

Phase 4

Antidotes

Phase 4

Expectorants

Phase 4

Immunologic Factors

Phase 4

Immune Sera

Phase 4

Clindamycin palmitate

Phase 4

Clindamycin phosphate

Phase 4

Alkylating Agents

Phase 4

Central Nervous System Depressants

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Antifungal Agents

Phase 4

Steroid Synthesis Inhibitors

Phase 4

Cytochrome P-450 CYP2C9 Inhibitors

Phase 4

Contraceptives, Oral

Phase 4

Contraceptive Agents

Phase 4

Progestins

Phase 4

Anesthetics

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Anesthetics, General

Phase 4

Anesthetics, Inhalation

Phase 4

Estrogens

Phase 4

Hormone Antagonists

Phase 4

Hormones

Phase 4

Estradiol 17 beta-cypionate

Phase 4

Estradiol 3-benzoate

Phase 4

Interventional clinical trials:

(show top 50) (show all 121)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis	Unknown status	NCT03080740	Phase 4	Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
2	Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy	Unknown status	NCT01558388	Phase 4	Lactobacillus acidophilus;Placebo
3	The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers	Unknown status	NCT01448291	Phase 4	Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
4	Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda	Unknown status	NCT02905890	Phase 4	Norethisterone enantate
5	Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis	Unknown status	NCT01841411	Phase 4	N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
6	Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole.	Completed	NCT00556179	Phase 4	Lactoserum (Dermacyd Femina®)
7	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis	Completed	NCT02392026	Phase 4	Metronidazole Gel
8	Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis	Completed	NCT02860845	Phase 4	Antibiotic (Clindamycin);Antifungal (Clotrimazole)
9	Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses	Completed	NCT01245322	Phase 4	lactobacilli
10	Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding	Completed	NCT00464542	Phase 4	Metronidazole
11	Tinidazole for the Treatment of Bacterial Vaginosis	Completed	NCT00334633	Phase 4	tinidazole, metronidazole
12	Therapy and Prevention for Sexually Associated Bacterial Vaginosis	Completed	NCT00324818	Phase 4	metronidazole and azithromycin
13	Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity	Completed	NCT02445989	Phase 4	NuvaRing
14	Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial	Completed	NCT01800825	Phase 4	Clindamycin;Placebo
15	Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy	Completed	NCT00642980	Phase 4	Clindamycin;Placebo;Clindamycin
16	Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females	Completed	NCT01310582	Phase 4	Desflurane;Sevoflurane
17	A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections	Recruiting	NCT03839875	Phase 4	Gynomax® XL Vaginal Ovule
18	Postmenopausal Pessary Users: Estrogen Versus Trimosan	Recruiting	NCT03943823	Phase 4	Estrogen vaginal cream;Trimo-San vaginal gel
19	A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis	Recruiting	NCT03099408	Phase 4	Metronidazole Oral;"Metronidazole" and "Lactobacillus"
20	Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital	Recruiting	NCT03894813	Phase 4	"Probiotics" and "Metronidazole";Metronidazole Vaginal
21	A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis	Recruiting	NCT03937869	Phase 4	Secnidazole
22	Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV)	Recruiting	NCT02042287	Phase 4	Metronidazole
23	The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study	Terminated	NCT01153958	Phase 4	Colposeptine;Metronidazole
24	Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis	Unknown status	NCT02173184	Phase 3
25	Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)	Unknown status	NCT00889356	Phase 3	Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
26	Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis	Unknown status	NCT01089348	Phase 2, Phase 3	Lactofiltrum + Metronidazole;Metronidazole
27	Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery	Unknown status	NCT00491270	Phase 3
28	VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY.	Unknown status	NCT01152528	Phase 3
29	The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial	Unknown status	NCT00536848	Phase 2, Phase 3	Metronidazole
30	A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis	Completed	NCT02418845	Phase 3	SYM-1219;Placebo
31	A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis	Completed	NCT01621399	Phase 3	Product 55394;Placebo Vehicle (non-treatment)
32	A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets.	Completed	NCT00229216	Phase 3	Tinidazole
33	The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis	Completed	NCT01258556	Phase 2, Phase 3
34	Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310	Completed	NCT01586364	Phase 3	Ospemifene 60Mg Oral Tablet
35	Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.	Completed	NCT01585558	Phase 3	Ospemifene (Dose 1);Ospemifene (Dose 2);Placebo
36	A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis	Completed	NCT03091777	Phase 3	GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
37	Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis	Completed	NCT01125410	Phase 3	Dequalinium chloride;Clindamycin
38	Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial	Completed	NCT01160796	Phase 3	placebo;Lcr35®
39	A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis	Completed	NCT01577537	Phase 3	1% SPL7013 Gel;Placebo
40	A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis	Completed	NCT01577238	Phase 3	1% SPL7013 Gel;Placebo
41	A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated	Completed	NCT01293643	Phase 3	100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
42	Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo	Completed	NCT00566982	Phase 3	Ospemifene 60 mg;Placebo
43	Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo	Completed	NCT00276094	Phase 3	Ospemifene 30 mg;Ospemifene 60 mg;Placebo;Nonhormonal vaginal lubricant
44	A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis	Completed	NCT02452866	Phase 3	SYM-1219
45	Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women	Completed	NCT00729469	Phase 3	Ospemifene 60 mg;Placebo
46	A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis	Completed	NCT02237950	Phase 3	Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
47	A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis.	Completed	NCT02236156	Phase 3	Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
48	A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women	Completed	NCT02210689	Phase 3	clindamycin phosphate vaginal cream 2%
49	A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge	Completed	NCT00313131	Phase 3	tinidazole+fluconazole vs metronidazole+clotrimazole
50	A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)	Completed	NCT01867164	Phase 3	Gynoclin V;Vagitrol V

Search NIH Clinical Center for Vaginal Disease

Cochrane evidence based reviews: vaginal diseases

Sources

Genetic Tests for Vaginal Disease

Sources

Anatomical Context for Vaginal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Disease:

¹⁹

Vagina

MalaCards organs/tissues related to Vaginal Disease:

⁴⁰

Bone, Testes, Colon, Lung, Liver, Cervix, Eye

Sources

Publications for Vaginal Disease

Articles related to Vaginal Disease:

(show top 50) (show all 117)

#	Title	Authors	PMID	Year
1	An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis. ⁴²	Marcotte H...Otwombe K	31533663	2019
2	Low-dose methotrexate-induced vulvar edema: A case report. ⁴²	Jia G...Gong F	31464920	2019
3	Vaginismus - who takes interest in it? ⁴²	Dankova Kucerova J...Vrana T	31324116	2019
4	MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study. ⁶¹	Chopra S...Shrivastava S	31682968	2020
5	Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China. ⁶¹	Li L...Wang J	31897224	2020
6	Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. ⁶¹	Xu L...Arbyn M	31718338	2019
7	Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. ⁶¹	Shukla A...Sobel JD	31707496	2019
8	Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study. ⁶¹	Agorastos T...Stamatopoulos K	31427275	2019
9	Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. ⁶¹	Pan J...Wakeham K	30650180	2019
10	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. ⁶¹	Giuliano AR...Luxembourg A	30982556	2019
11	Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study. ⁶¹	Fokom Domgue J...Schmeler KM	30827725	2019
12	Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. ⁶¹	Barcellini A...Orecchia R	30804128	2019
13	Newly Isolated Lactobacilli strains from Algerian Human Vaginal Microbiota: Lactobacillus fermentum Strains Relevant Probiotic's Candidates. ⁶¹	Ouarabi L...Bendali F	29185234	2019
14	Can We Improve Vaginal Tissue Healing Using Customized Devices: 3D Printing and Biomechanical Changes in Vaginal Tissue. ⁶¹	Hakim J...Dietrich JE	30269139	2019
15	Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome. ⁶¹	Riepl M	30384345	2018
16	Regulation of Herpes Simplex Virus 2 Protein Kinase UL13 by Phosphorylation and Its Role in Viral Pathogenesis. ⁶¹	Koyanagi N...Kawaguchi Y	29899106	2018
17	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. ⁶¹	Huh WK...Luxembourg A	28886907	2017
18	Novel ex vivo protocol using porcine vagina to assess drug permeation from mucoadhesive and colloidal pharmaceutical systems. ⁶¹	Pereira MN...Gelfuso GM	28697437	2017
19	Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. ⁶¹	Signorelli C...Peracino A	28446260	2017
20	Vulvar and Vaginal Graft versus Host Disease: A Healthcare Clinic Initiative. ⁶¹	Van Dam N...Frank-Kamenetsky Y	28503642	2017
21	Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. ⁶¹	He Y...Wu YM	28445274	2017
22	Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. ⁶¹	Donders GGG...Unemo M	29017160	2017
23	Biotherapeutic agents and vaginal health. ⁶¹	Al-Ghazzewi FH...Tester RF	26757173	2016
24	Baboon vaginal microbial flora. ⁶¹	Obiero JA...Mwethera PG	27198467	2016
25	Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. ⁶¹	Boiron L...Uhart M	27084683	2016
26	Magnetic resonance imaging of the vagina: an overview for radiologists with emphasis on clinical decision making. ⁶¹	Ferreira DM...Rocha Mde S	26379324	2015
27	A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. ⁶¹	Joura EA...Broad Spectrum HPV Vaccine Study	25693011	2015
28	Clinical characteristics of non-squamous cell carcinoma of the vagina. ⁶¹	Nomura H...Takeshima N	25594143	2015
29	Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. ⁶¹	Wagner M...Weiss TW	25987893	2015
30	Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer. ⁶¹	Shin SM...Lymberis SC	26442213	2015
31	Spray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structure. ⁶¹	Wu N...Li J	26347257	2015
32	[Group A streptococcal perineal infection in children]. ⁶¹	Koskas M...Cohen R	25456689	2014
33	Botryomycosis of the vulva: a case report. ⁶¹	Elas D...Stockdale C	24402357	2014
34	First clinical implementation of the Capri applicator. ⁶¹	Gloi AM	24423857	2014
35	β-Glucan induces reactive oxygen species production in human neutrophils to improve the killing of Candida albicans and Candida glabrata isolates from vulvovaginal candidiasis. ⁶¹	Bonfim-Mendonca Pde S...Svidzinski TI	25229476	2014
36	Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. ⁶¹	Liu Z...Zhang W	23845900	2013
37	[Laparoscopic radical hysterectomy after initial brachytherapy for stage IB1 cervical cancer: feasibility and results]. ⁶¹	Uzan C...Leblanc E	24139815	2013
38	Nanopharmaceuticals for improved topical vaginal therapy: can they deliver? ⁶¹	Vanic Z...Skalko-Basnet N	23684936	2013
39	Laparoscopic radical hysterectomy after preoperative brachytherapy for stage IB1 cervical cancer: feasibility, results, and surgical implications in a large bicentric study of 162 consecutive cases. ⁶¹	Uzan C...Leblanc E	22932859	2013
40	Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy. ⁶¹	Diavolitsis V...Small W	22365625	2012
41	Subtotal vaginectomy for management of extensive vaginal disease in 11 dogs. ⁶¹	Nelissen P...White RA	22292563	2012
42	Role of vulvar care guidelines in the initial management of vulvar complaints. ⁶¹	Lifits-Podorozhansky YM...Gavard JA	22227837	2012
43	Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. ⁶¹	Awasthi S...Friedman HM	22318147	2012
44	Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease. ⁶¹	Kim JJ	22454090	2012
45	A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats. ⁶¹	Marinaro M...Tempesta M	22511971	2012
46	Vaginal use of Ibuprofen isobutanolammonium (ginenorm): efficacy, tolerability, and pharmacokinetic data: a review of available data. ⁶¹	Milani M...Iacobelli P	22844609	2012
47	Evaluation of the VITOM in digital high-definition video exocolposcopy. ⁶¹	Vercellino GF...Schneider A	21558961	2011
48	Overlooked diseases of the vagina: a directed anatomic-pathologic approach for imaging assessment. ⁶¹	Walker DK...Palmer SL	21997983	2011
49	Validation of the ethnopharmacological use of Polygonum persicaria for its antifungal properties. ⁶¹	Derita M...Zacchino S	21834226	2011
50	Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. ⁶¹	Unlu C...Donders G	24592002	2011

Sources

Genes for Vaginal Disease

Genes related to Vaginal Disease (0 elite genes):

(show all 36)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	9.41	DISEASES inferred ¹⁵ ¹⁵
2	CD4	CD4 Molecule	Protein Coding	7.74	DISEASES inferred ¹⁵
3	TLR7	Toll Like Receptor 7	Protein Coding	7.4	DISEASES inferred ¹⁵
4	SLPI	Secretory Leukocyte Peptidase Inhibitor	Protein Coding	7.27	DISEASES inferred ¹⁵
5	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	7.08	DISEASES inferred ¹⁵
6	LINC01191	Long Intergenic Non-Protein Coding RNA 1191	RNA Gene	7.08	DISEASES inferred ¹⁵
7	H2AC18	H2A Clustered Histone 18	Protein Coding	7.04	DISEASES inferred ¹⁵ ¹⁵
8	IL6	Interleukin 6	Protein Coding	7.01	DISEASES inferred ¹⁵
9	GP5	Glycoprotein V Platelet	Protein Coding	6.99	DISEASES inferred ¹⁵
10	CLEC7A	C-Type Lectin Domain Containing 7A	Protein Coding	6.9	DISEASES inferred ¹⁵
11	TLR4	Toll Like Receptor 4	Protein Coding	6.88	DISEASES inferred ¹⁵
12	TLR2	Toll Like Receptor 2	Protein Coding	6.87	DISEASES inferred ¹⁵
13	CD8A	CD8a Molecule	Protein Coding	6.78	DISEASES inferred ¹⁵
14	TLR8	Toll Like Receptor 8	Protein Coding	6.76	DISEASES inferred ¹⁵
15	TLR9	Toll Like Receptor 9	Protein Coding	6.75	DISEASES inferred ¹⁵
16	IL1B	Interleukin 1 Beta	Protein Coding	6.71	DISEASES inferred ¹⁵
17	TNF	Tumor Necrosis Factor	Protein Coding	6.71	DISEASES inferred ¹⁵
18	TLR3	Toll Like Receptor 3	Protein Coding	6.68	DISEASES inferred ¹⁵
19	CCR5	C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)	Protein Coding	6.63	DISEASES inferred ¹⁵
20	IL10	Interleukin 10	Protein Coding	6.63	DISEASES inferred ¹⁵
21	ATAD2	ATPase Family AAA Domain Containing 2	Protein Coding	6.57	DISEASES inferred ¹⁵
22	TLR1	Toll Like Receptor 1	Protein Coding	6.56	DISEASES inferred ¹⁵
23	DEFB4A	Defensin Beta 4A	Protein Coding	6.55	DISEASES inferred ¹⁵
24	TLR6	Toll Like Receptor 6	Protein Coding	6.49	DISEASES inferred ¹⁵
25	TP53	Tumor Protein P53	Protein Coding	6.45	DISEASES inferred ¹⁵
26	TLR5	Toll Like Receptor 5	Protein Coding	6.43	DISEASES inferred ¹⁵
27	CARD9	Caspase Recruitment Domain Family Member 9	Protein Coding	6.42	DISEASES inferred ¹⁵
28	TLR10	Toll Like Receptor 10	Protein Coding	6.41	DISEASES inferred ¹⁵
29	FN1	Fibronectin 1	Protein Coding	6.36	DISEASES inferred ¹⁵
30	SPTB	Spectrin Beta, Erythrocytic	Protein Coding	6.36	DISEASES inferred ¹⁵
31	IL17A	Interleukin 17A	Protein Coding	6.35	DISEASES inferred ¹⁵
32	IL2	Interleukin 2	Protein Coding	6.29	DISEASES inferred ¹⁵
33	CRP	C-Reactive Protein	Protein Coding	6.29	DISEASES inferred ¹⁵
34	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	6.28	DISEASES inferred ¹⁵
35	SKAP2	Src Kinase Associated Phosphoprotein 2	Protein Coding	6.25	DISEASES inferred ¹⁵
36	CAMP	Cathelicidin Antimicrobial Peptide	Protein Coding	6.23	DISEASES inferred ¹⁵

Sources

Variations for Vaginal Disease

Sources

Expression for Vaginal Disease

Search GEO for disease gene expression data for Vaginal Disease.

Sources

Pathways for Vaginal Disease

Pathways related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 67)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.09	TNF TLR9 TLR8 TLR7 TLR4 TLR3
2	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.73	TNF TLR4 IL6 IL1B IL10 CXCL8
3	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.4	TNF TLR9 TLR8 TLR7 TLR4 TLR3
4	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.39	TNF IL6 IL1B IL10 CXCL8 CD4
5	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.31	TNF TLR9 TLR8 TLR7 TLR4 TLR3
6	Toll-like Receptor Signaling Pathway ¹ ³⁶ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ NOD-like Receptor Signaling Pathways ⁶⁴ Regulation of toll-like receptor signaling pathway ¹	13.23	TNF TLR9 TLR8 TLR7 TLR4 TLR3
7	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	13.1	TNF TLR4 TLR3 TLR2 IL6 IL1B
8	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.97	TNF IL6 IL1B IL10 CXCL8 CD8A
9	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.97	TNF TLR9 TLR7 TLR4 TLR3 TLR2
10	Herpes simplex virus 1 infection ³⁶	12.89	TNF TLR9 TLR3 TLR2 IL6 IL1B
11	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways ⁶⁵ Show member pathways Cytosolic DNA-sensing pathway ³⁶ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of RIG-I/MDA5 signaling ⁶⁵ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁵ RIG-I-like Receptor Signaling ¹ RIG-I-like receptor signaling pathway ³⁶ TRAF3-dependent IRF activation pathway ⁶⁵ TRAF6 mediated IRF7 activation ⁶⁵ Virus Detection and Induction of Antiviral Signaling Pathways by RIG-I-like Receptors (RLR) ⁶⁴	12.86	TNF TLR4 TLR3 IL6 IL1B CXCL8
12	NF-KappaB Family Pathway ⁶³ Show member pathways NF-KappaB (p50-p65) Pathway ⁶³	12.85	TNF TLR9 TLR8 TLR7 TLR4 TLR3
13	TRAF Pathway ⁶³ Show member pathways 14-3-3 Induced Apoptosis ⁶³ TNF Superfamily Pathway ⁶³ Toll-Like Receptors Pathway ⁶³	12.76	TNF TLR9 TLR8 TLR7 TLR4 TLR3
14	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶³ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.74	TNF TLR4 TLR2 IL6 IL1B IL10
15	NF-kappaB Signaling ⁴	12.68	TNF TLR9 TLR8 TLR7 TLR3 TLR2
16	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.66	TNF IL6 IL1B IL10 CD4
17	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.61	TNF TLR9 TLR4 TLR2 IL6 IL1B
18	VEGF Pathway (Qiagen) ⁶³ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶³ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁵ VEGF Family Ligands and Receptor Interactions ⁶³	12.53	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
19	Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions ⁶⁴ Show member pathways Chemokine receptors bind chemokines ⁶⁵ Viral protein interaction with cytokine and cytokine receptor ³⁶	12.47	TNF IL6 IL10 CXCL8 CCR6 CCR5
20	Toll Comparative Pathway ⁶³ Show member pathways IL-1 Pathway ⁶³ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶³ TLR-TRIF Pathway ⁶³	12.45	TNF TLR4 TLR3 IL6 IL1B CXCL8
21	IL-17 Family Signaling Pathways ⁶⁴ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁶ Interleukin-17 signaling ⁶⁵ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.44	TNF TLR2 IL6 IL1B CXCL8
22	Shigellosis ³⁶	12.41	TNF TLR4 IL1B CXCL8
23	Pathogenic Escherichia coli infection ³⁶	12.41	TNF TLR4 IL6 IL1B CXCL8
24	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.41	TNF TLR4 TLR2 IL1B IL10 CCR5
25	C-type lectin receptor signaling pathway ³⁶ Show member pathways Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁴	12.39	TNF TLR9 TLR8 IL6 IL1B IL10
26	NOD-like receptor signaling pathway ³⁶	12.36	TNF TLR4 IL6 IL1B CXCL8
27	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.34	TNF IL6 IL1B IL10 CXCL8
28	IL-1 Family Signaling Pathways ⁶⁴ Show member pathways Immune response IL-1 signaling pathway ²² Mucin expression in CF via TLRs, EGFR signaling pathways ²²	12.34	TNF TLR2 IL6 IL1B CXCL8
29	Necroptosis ³⁶ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.33	TNF TLR4 TLR3 IL1B H2AC18
30	Tuberculosis ³⁶	12.33	TNF TLR9 TLR4 TLR2 IL6 IL1B
31	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.29	TNF IL6 IL1B IL10 CXCL8
32	Colorectal Cancer Metastasis ⁶³	12.28	TNF TLR9 TLR8 TLR7 TLR4 TLR3
33	Diseases associated with the TLR signaling cascade ⁶⁵ Show member pathways Diseases of Immune System ⁶⁵ Interleukin-1 Induced Activation of NF-kappa-B ¹ IRAK1 recruits IKK complex ⁶⁵ IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation ⁶⁵ IRAK4 deficiency (TLR2/4) ⁶⁵ IRAK4 deficiency (TLR5) ⁶⁵ MyD88 deficiency (TLR2/4) ⁶⁵ MyD88 deficiency (TLR5) ⁶⁵ Simplified Depiction of MYD88 Distinct Input-Output Pathway ¹ TLR4 Signaling and Tolerance ¹ Toll-like Receptor Signaling ¹	12.25	TNF TLR9 TLR8 TLR7 TLR4 TLR3
34	Yersinia infection ³⁶	12.2	TNF TLR4 IL6 IL1B IL10 CXCL8
35	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁴	12.18	TNF IL6 IL10 GP5 CD8A CD4
36	Microglia Activation During Neuroinflammation: Overview ⁶⁴ Show member pathways Microglia Activation During Neuroinflammation: Microglia Activation ⁶⁴	12.17	TNF TLR4 TLR2 IL6 IL1B
37	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.17	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
38	Spinal Cord Injury ¹	12.15	TNF TLR4 IL6 IL1B CXCL8
39	Bacterial infections in CF airways ²² Show member pathways IL-1 beta-dependent CFTR expression ²² Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²²	12.13	TNF TLR9 TLR8 TLR7 TLR4 TLR2
40	Interleukin-4 and 13 signaling ⁶⁵	12.12	TNF IL6 IL1B IL10 CXCL8
41	Hematopoietic cell lineage ³⁶	12.11	TNF IL6 IL1B GP5 CD8A CD4
42	IL12-mediated signaling events ¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.08	IL1B CD8A CD4 CCR5
43	Rheumatoid arthritis ³⁶	12.07	TNF TLR4 TLR2 IL6 IL1B CXCL8
44	Amoebiasis ³⁶	12.05	TNF TLR4 TLR2 IL6 IL1B IL10
45	NF-kappa B signaling pathway ³⁶	12.03	TNF TLR4 IL1B CXCL8
46	AGE-RAGE signaling pathway in diabetic complications ³⁶	12.02	TNF IL6 IL1B CXCL8
47	Innate Lymphoid Cell Differentiation Pathways ⁶⁴	11.98	TNF IL1B IL10 CD8A CD4 CCR6
48	Pertussis ³⁶	11.94	TNF TLR4 IL6 IL1B IL10 CXCL8
49	Salmonella infection (KEGG) ³⁶	11.91	TLR4 IL6 IL1B CXCL8
50	Phagocytosis of Microbes ⁶³	11.91	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2

Sources

GO Terms for Vaginal Disease

Cellular components related to Vaginal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.91	TNF TLR4 TLR3 TLR2 GP5 CD8A
2	cell surface	GO:0009986	9.76	TNF TLR4 TLR3 TLR2 CLEC7A CD4
3	endosome membrane	GO:0010008	9.72	TLR9 TLR8 TLR7 TLR4 TLR3
4	external side of plasma membrane	GO:0009897	9.5	TNF TLR8 TLR4 CD8A CD4 CCR6
5	endolysosome membrane	GO:0036020	8.92	TLR9 TLR8 TLR7 TLR3

Biological processes related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 86)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.4	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
2	positive regulation of transcription by RNA polymerase II	GO:0045944	10.32	TNF TLR9 TLR4 TLR3 TLR2 IL6
3	immune system process	GO:0002376	10.26	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
4	innate immune response	GO:0045087	10.23	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
5	positive regulation of gene expression	GO:0010628	10.21	TNF TLR9 TLR4 TLR3 TLR2 IL6
6	negative regulation of cell proliferation	GO:0008285	10.16	TLR2 IL6 IL1B IL10 CXCL8
7	cytokine-mediated signaling pathway	GO:0019221	10.16	TNF IL6 IL1B IL10 CXCL8 CD4
8	defense response to bacterium	GO:0042742	10.14	TNF TLR9 TLR4 TLR3 SLPI IL10
9	cellular response to lipopolysaccharide	GO:0071222	10.12	TNF TLR4 IL6 IL1B IL10 CXCL8
10	defense response to virus	GO:0051607	10.1	TLR9 TLR8 TLR7 TLR3 IL6
11	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	10.1	TNF TLR9 TLR4 TLR3 IL1B CD4
12	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.09	TNF TLR9 TLR4 TLR3 TLR2 IL6
13	response to lipopolysaccharide	GO:0032496	10.08	TLR4 TLR2 SLPI IL1B IL10
14	positive regulation of JNK cascade	GO:0046330	10.05	TNF TLR9 TLR4 TLR3 IL1B
15	cellular response to mechanical stimulus	GO:0071260	10.04	TLR8 TLR7 TLR4 TLR3 IL1B
16	defense response	GO:0006952	10.03	TNF TLR3 CXCL8 CCR5
17	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.02	TNF IL6 IL1B IL10
18	positive regulation of inflammatory response	GO:0050729	10.02	TNF TLR9 TLR7 TLR4 TLR3 TLR2
19	I-kappaB kinase/NF-kappaB signaling	GO:0007249	10.01	TNF TLR9 TLR8 TLR7 TLR4 TLR3
20	defense response to Gram-negative bacterium	GO:0050829	10	TLR9 TLR4 IL6 CD4
21	toll-like receptor signaling pathway	GO:0002224	9.99	TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
22	positive regulation of interleukin-6 secretion	GO:2000778	9.98	TNF TLR8 TLR4 TLR2 IL1B
23	positive regulation of tumor necrosis factor production	GO:0032760	9.97	TLR9 TLR4 TLR3 TLR2
24	positive regulation of nitric oxide biosynthetic process	GO:0045429	9.97	TNF TLR4 IL1B CLEC7A
25	MyD88-dependent toll-like receptor signaling pathway	GO:0002755	9.97	TLR9 TLR8 TLR7 TLR4 TLR2
26	negative regulation of interleukin-6 production	GO:0032715	9.96	TNF TLR9 TLR4 IL10
27	lipopolysaccharide-mediated signaling pathway	GO:0031663	9.96	TNF TLR4 TLR2 IL1B
28	microglial cell activation	GO:0001774	9.96	TNF TLR8 TLR7 TLR3 TLR2
29	positive regulation of interleukin-12 production	GO:0032735	9.95	TLR9 TLR4 TLR3 TLR2
30	positive regulation of NIK/NF-kappaB signaling	GO:1901224	9.95	TNF TLR9 TLR7 TLR4 TLR3 TLR2
31	chemokine-mediated signaling pathway	GO:0070098	9.94	CXCL8 CCR6 CCR5
32	positive regulation of interferon-beta production	GO:0032728	9.94	TLR9 TLR4 TLR3 TLR2
33	response to glucocorticoid	GO:0051384	9.93	TNF IL6 IL10
34	apoptotic signaling pathway	GO:0097190	9.93	TNF TLR4 TLR3
35	regulation of protein phosphorylation	GO:0001932	9.93	TNF TLR8 TLR7
36	positive regulation of T cell proliferation	GO:0042102	9.93	IL6 IL1B CD4
37	humoral immune response	GO:0006959	9.92	TNF IL6 CCR6
38	T cell activation	GO:0042110	9.92	CLEC7A CD8A CD4
39	positive regulation of phagocytosis	GO:0050766	9.91	TNF IL1B CLEC7A
40	positive regulation of interferon-gamma production	GO:0032729	9.91	TNF TLR4 IL1B
41	positive regulation of JAK-STAT cascade	GO:0046427	9.9	TNF IL6 IL10
42	response to molecule of bacterial origin	GO:0002237	9.9	TLR9 TLR2 IL10 CXCL8
43	negative regulation of neurogenesis	GO:0050768	9.89	TNF IL6 IL1B
44	positive regulation of interferon-gamma biosynthetic process	GO:0045078	9.89	TLR9 TLR8 TLR7 TLR3 CLEC7A
45	positive regulation of interleukin-10 production	GO:0032733	9.88	TLR9 TLR4 TLR2
46	positive regulation of glial cell proliferation	GO:0060252	9.87	TNF IL6 IL1B
47	toll-like receptor 9 signaling pathway	GO:0034162	9.87	TLR9 TLR8 TLR7
48	positive regulation of heterotypic cell-cell adhesion	GO:0034116	9.87	TNF IL1B IL10
49	positive regulation of nitric-oxide synthase biosynthetic process	GO:0051770	9.87	TLR9 TLR4 TLR2
50	positive regulation of interleukin-8 production	GO:0032757	9.87	TNF TLR9 TLR7 TLR4 TLR3 TLR2

Molecular functions related to Vaginal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.36	TNF TLR9 TLR8 TLR7 TLR4 TLR3
2	cytokine activity	GO:0005125	9.65	TNF IL6 IL1B IL10 CXCL8
3	signaling receptor activity	GO:0038023	9.63	TLR8 TLR4 TLR3 TLR2 CD4 CCR6
4	double-stranded RNA binding	GO:0003725	9.61	TLR8 TLR7 TLR3
5	coreceptor activity	GO:0015026	9.5	CD8A CD4 CCR5
6	transmembrane signaling receptor activity	GO:0004888	9.43	TLR9 TLR8 TLR7 TLR4 TLR3 CD4
7	lipopolysaccharide receptor activity	GO:0001875	9.37	TLR4 TLR2
8	signaling pattern recognition receptor activity	GO:0008329	9.02	TLR9 TLR8 TLR7 TLR2 CLEC7A

Sources

Sources for Vaginal Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia